{
    "id": 1798,
    "fullName": "BRCA1 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "BRCA1 loss indicates loss of the BRCA1 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 672,
        "geneSymbol": "BRCA1",
        "terms": [
            "BRCA1",
            "BRCAI",
            "BRCC1",
            "BROVCA1",
            "FANCS",
            "IRIS",
            "PNCA4",
            "PPP1R53",
            "PSCP",
            "RNF53"
        ]
    },
    "variant": "loss",
    "createDate": "09/18/2014",
    "updateDate": "07/30/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8663,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lynparza (olaparib) treatment resulted in prolonged overall survival in BRCA1 deficient transgenic mouse models of breast cancer (PMID: 27454287).",
            "molecularProfile": {
                "id": 1787,
                "profileName": "BRCA1 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6707,
                    "pubMedId": 27454287,
                    "title": "BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27454287"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20448,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment sensitized BRCA1 deficient breast cancer cells to Temodar (temozolomide), and synergistically inhibited proliferation in culture, and inhibited tumor growth and induced partial regression in a cell line xenograft model (PMID: 30663191).",
            "molecularProfile": {
                "id": 1787,
                "profileName": "BRCA1 loss"
            },
            "therapy": {
                "id": 9363,
                "therapyName": "Fluzoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20444,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment inhibited proliferation, and induced cell cycle arrest and apoptosis in BRCA1 deficient breast cancer cells in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 30663191).",
            "molecularProfile": {
                "id": 1787,
                "profileName": "BRCA1 loss"
            },
            "therapy": {
                "id": 9101,
                "therapyName": "Fluzoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20445,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment inhibited proliferation of BRCA1 deficient ovarian cancer cells in culture (PMID: 30663191).",
            "molecularProfile": {
                "id": 1787,
                "profileName": "BRCA1 loss"
            },
            "therapy": {
                "id": 9101,
                "therapyName": "Fluzoparib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1057,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, high dose Paraplatin (carboplatin) chemotherapy was more beneficial for breast cancer patients with BRCA1 loss than was conventional anthracycline-based chemotherapy (PMID: 21135055).",
            "molecularProfile": {
                "id": 1787,
                "profileName": "BRCA1 loss"
            },
            "therapy": {
                "id": 1092,
                "therapyName": "Carboplatin",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 768,
                    "pubMedId": 21135055,
                    "title": "An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21135055"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8945,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast cancer model lacking both BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455).",
            "molecularProfile": {
                "id": 26544,
                "profileName": "BRCA1 loss TP53 loss"
            },
            "therapy": {
                "id": 2542,
                "therapyName": "AZD2461",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6793,
                    "pubMedId": 27550455,
                    "title": "The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550455"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13769,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with a combination of BGJ398 and Talazoparib (BMN-673) demonstrated a complete response and no relapse within 80 days (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 6895,
                "therapyName": "BGJ398 + Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13764,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 were sensitive to treatment with BGJ398, demonstrating tumor regression, however, after 43 days on average, three out of six models developed resistance (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13766,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring FGFR2-DNM3 treated with a combination of BGJ398 and Lynparza (olaparib) demonstrated a complete response and did not develop resistance as compared to those models treated with BGJ398 alone (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 6894,
                "therapyName": "BGJ398 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13765,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models treated with BKM120 demonstrated only delayed tumor progression when compared to treatment with BGJ398, which resulted in tumor regression (PMID: 29203461).",
            "molecularProfile": {
                "id": 29408,
                "profileName": "FGFR2 - DNM3 BRCA1 loss"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13789,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring DHX9-RAF1 initially demonstrated slow tumor growth when treated with Mekinist (trametinib), eventually resulting in stable disease, however, after 14 days progression ensued (PMID: 29203461).",
            "molecularProfile": {
                "id": 29428,
                "profileName": "DHX9 - RAF1 BRCA1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13798,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring DHX9-RAF1 demonstrated complete tumor regression when treated with the combination therapy of Lynparza (olaparib) and Mekinist (trametinib) (PMID: 29203461).",
            "molecularProfile": {
                "id": 29428,
                "profileName": "DHX9 - RAF1 BRCA1 loss"
            },
            "therapy": {
                "id": 6896,
                "therapyName": "Olaparib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13800,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRCA1-deficient triple-receptor negative breast cancer xenograft models harboring DHX9-RAF1 demonstrated slow tumor regression when treated with Lynparza (olaparib) (PMID: 29203461).",
            "molecularProfile": {
                "id": 29428,
                "profileName": "DHX9 - RAF1 BRCA1 loss"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11267,
                    "pubMedId": 29203461,
                    "title": "Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29203461"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20449,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment sensitized BRCA1 deficient and BRCA2 mutant breast cancer cells to Temodar (temozolomide), and synergistically inhibited proliferation in culture, and inhibited tumor growth and induced partial regression in a cell line xenograft model (PMID: 30663191).",
            "molecularProfile": {
                "id": 35178,
                "profileName": "BRCA1 loss BRCA2 mut"
            },
            "therapy": {
                "id": 9363,
                "therapyName": "Fluzoparib + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Fluzoparib treatment inhibited proliferation of breast cancer cells harboring a BRCA2 mutation and BRCA1 deficiency in culture (PMID: 30663191).",
            "molecularProfile": {
                "id": 35178,
                "profileName": "BRCA1 loss BRCA2 mut"
            },
            "therapy": {
                "id": 9101,
                "therapyName": "Fluzoparib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17840,
                    "pubMedId": 30663191,
                    "title": "Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30663191"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1787,
            "profileName": "BRCA1 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 17585,
                    "name": "PARP Inhibitor (Pan)",
                    "profileName": "BRCA1 loss"
                },
                {
                    "id": 17584,
                    "name": "PARP-1 Inhibitor",
                    "profileName": "BRCA1 loss"
                }
            ]
        },
        {
            "id": 26544,
            "profileName": "BRCA1 loss TP53 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29408,
            "profileName": "FGFR2 - DNM3 BRCA1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29428,
            "profileName": "DHX9 - RAF1 BRCA1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35178,
            "profileName": "BRCA1 loss BRCA2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}